Cantor Fitzgerald notes that the firm discovered ... the high-level news commentary “sounds very positive” for mevrometostat and Oric Pharmaceuticals (ORIC). The firm has an Overweight ...
Hosted on MSN1mon
ORIC Pharmaceuticals shares surge on potential data leakInvesting.com -- ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid a possible leak of encouraging clinical trial data.
1d
PNC Financial Services Group Inc. raised its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 22.9% during ...
Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. JPMorgan Chase & Co. increased their price objective on ORIC ...
On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback